FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2153005915> ?p ?o ?g. }

• W2153005915 endingPage "935" @default.
• W2153005915 startingPage "935" @default.
• W2153005915 abstract "Up to 3 years of treatment with alendronate, 5 mg/d, prevents postmenopausal bone loss.To determine whether the effect of alendronate is sustained at 4 years of treatment and persists after treatment is discontinued.Randomized, controlled trial.United States and Europe.1609 postmenopausal women 45 to 59 years of age.Participants were randomly assigned to receive oral alendronate, 5 mg/d or 2.5 mg/d; placebo; or open-label estrogen-progestin. Women in the alendronate groups received alendronate for the first 2 years of the study. Treatment was then continued without change or replaced with placebo for the last 2 years of the study.Annual measurement of bone mineral density.By year 4, the bone mineral density of participants in the placebo group had decreased by 1% to 6% (P < 0.001). Four years of treatment with 5 mg of alendronate per day increased bone mineral density at the spine (mean change [+/-SE], 3.8%+/-0.3%), hip (mean, 2.9%+/-0.2%), and total body (mean, 0.9%+/-0.2%) (P < 0.001 overall). By year 4, bone mineral density at most skeletal sites was greater in participants who switched from alendronate to placebo than in those who continuously received placebo. In years 3 and 4, bone loss in participants who switched from alendronate to placebo was similar to that seen during years 1 and 2 in those who continuously received placebo. Compared with 5 mg of alendronate per day, estrogen-medroxyprogesterone acetate produced similar increases in bone mineral density and estradiol-norethisterone acetate produced increases that were substantially greater.Four years of treatment with alendronate or estrogen-progestin prevented postmenopausal bone loss. A residual effect was seen 2 years after alendronate therapy was stopped; however, continuous alendronate treatment was more effective in preventing postmenopausal bone loss than 2 years of alendronate followed by 2 years of placebo." @default.
• W2153005915 created "2016-06-24" @default.
• W2153005915 creator A5007638945 @default.
• W2153005915 creator A5016432042 @default.
• W2153005915 creator A5032335007 @default.
• W2153005915 creator A5032904447 @default.
• W2153005915 creator A5043349829 @default.
• W2153005915 creator A5048725197 @default.
• W2153005915 creator A5051760233 @default.
• W2153005915 creator A5052103282 @default.
• W2153005915 creator A5062652251 @default.
• W2153005915 creator A5067068470 @default.
• W2153005915 creator A5080823270 @default.
• W2153005915 date "1999-12-21" @default.
• W2153005915 modified "2023-10-06" @default.
• W2153005915 title "Alendronate and Estrogen–Progestin in the Long-Term Prevention of Bone Loss: Four-Year Results from the Early Postmenopausal Intervention Cohort Study: A Randomized, Controlled Trial" @default.
• W2153005915 cites W1966019630 @default.
• W2153005915 cites W1973586346 @default.
• W2153005915 cites W1993932749 @default.
• W2153005915 cites W2004236425 @default.
• W2153005915 cites W2006021879 @default.
• W2153005915 cites W2010793737 @default.
• W2153005915 cites W2047928737 @default.
• W2153005915 cites W2066739013 @default.
• W2153005915 cites W2070632695 @default.
• W2153005915 cites W2075992155 @default.
• W2153005915 cites W2078406992 @default.
• W2153005915 cites W2080640278 @default.
• W2153005915 cites W2097506722 @default.
• W2153005915 cites W2104949625 @default.
• W2153005915 cites W2126253382 @default.
• W2153005915 cites W2136643008 @default.
• W2153005915 cites W2151649765 @default.
• W2153005915 cites W2153009489 @default.
• W2153005915 cites W2313507666 @default.
• W2153005915 cites W2321227665 @default.
• W2153005915 cites W2336517627 @default.
• W2153005915 cites W2340685677 @default.
• W2153005915 cites W2783103906 @default.
• W2153005915 cites W4245166850 @default.
• W2153005915 doi "https://doi.org/10.7326/0003-4819-131-12-199912210-00005" @default.
• W2153005915 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10610644" @default.
• W2153005915 hasPublicationYear "1999" @default.
• W2153005915 type Work @default.
• W2153005915 sameAs 2153005915 @default.
• W2153005915 citedByCount "170" @default.
• W2153005915 countsByYear W21530059152012 @default.
• W2153005915 countsByYear W21530059152013 @default.
• W2153005915 countsByYear W21530059152014 @default.
• W2153005915 countsByYear W21530059152015 @default.
• W2153005915 countsByYear W21530059152016 @default.
• W2153005915 countsByYear W21530059152017 @default.
• W2153005915 countsByYear W21530059152018 @default.
• W2153005915 countsByYear W21530059152019 @default.
• W2153005915 countsByYear W21530059152020 @default.
• W2153005915 countsByYear W21530059152021 @default.
• W2153005915 countsByYear W21530059152022 @default.
• W2153005915 countsByYear W21530059152023 @default.
• W2153005915 crossrefType "journal-article" @default.
• W2153005915 hasAuthorship W2153005915A5007638945 @default.
• W2153005915 hasAuthorship W2153005915A5016432042 @default.
• W2153005915 hasAuthorship W2153005915A5032335007 @default.
• W2153005915 hasAuthorship W2153005915A5032904447 @default.
• W2153005915 hasAuthorship W2153005915A5043349829 @default.
• W2153005915 hasAuthorship W2153005915A5048725197 @default.
• W2153005915 hasAuthorship W2153005915A5051760233 @default.
• W2153005915 hasAuthorship W2153005915A5052103282 @default.
• W2153005915 hasAuthorship W2153005915A5062652251 @default.
• W2153005915 hasAuthorship W2153005915A5067068470 @default.
• W2153005915 hasAuthorship W2153005915A5080823270 @default.
• W2153005915 hasConcept C126322002 @default.
• W2153005915 hasConcept C126894567 @default.
• W2153005915 hasConcept C141071460 @default.
• W2153005915 hasConcept C142724271 @default.
• W2153005915 hasConcept C168563851 @default.
• W2153005915 hasConcept C204787440 @default.
• W2153005915 hasConcept C27081682 @default.
• W2153005915 hasConcept C2775934596 @default.
• W2153005915 hasConcept C2776306185 @default.
• W2153005915 hasConcept C2776541429 @default.
• W2153005915 hasConcept C2776886416 @default.
• W2153005915 hasConcept C2777164284 @default.
• W2153005915 hasConcept C2779329777 @default.
• W2153005915 hasConcept C2779809032 @default.
• W2153005915 hasConcept C2781039349 @default.
• W2153005915 hasConcept C2908647359 @default.
• W2153005915 hasConcept C2986817661 @default.
• W2153005915 hasConcept C71924100 @default.
• W2153005915 hasConcept C99454951 @default.
• W2153005915 hasConceptScore W2153005915C126322002 @default.
• W2153005915 hasConceptScore W2153005915C126894567 @default.
• W2153005915 hasConceptScore W2153005915C141071460 @default.
• W2153005915 hasConceptScore W2153005915C142724271 @default.
• W2153005915 hasConceptScore W2153005915C168563851 @default.
• W2153005915 hasConceptScore W2153005915C204787440 @default.
• W2153005915 hasConceptScore W2153005915C27081682 @default.
• W2153005915 hasConceptScore W2153005915C2775934596 @default.
• W2153005915 hasConceptScore W2153005915C2776306185 @default.

• next